CD274 and lung carcinoma: In conclusion, for the long-term treatment of lung cancer patients, an appropriate dose and targeted combination and dosing regimen based on individual patient differences and tolerance to the drug that provides the best combination strategy to expand anti-PD-1/PD-L1-based immunotherapy can greatly improve the prognosis and quality of life for a patient.